Blood coagulation protein conjugates
View Patent ↗The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a blood coagulation protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer. In one embodiment of the invention the conjugation is carried out in the presence of the nucleophilic catalyst aniline. In addition the generated oxime linkage can be stabilized by reduction with NaCNBH 3 to form an alkoxyamine linkage.
1. A modified blood coagulation protein comprising:
(a) a blood coagulation protein selected from the group consisting of
i) a blood coagulation protein with Factor IX (FIX) biological activity; and
ii) a blood coagulation protein with Factor VIII (FVIII) biological activity; and
(b) at least one polysialic acid (PSA) containing an active aminooxy group bound to said blood coagulation protein of (a) at one or more oxidized carbohydrate moieties;
wherein said modified blood coagulation protein has an oxime linkage between said one or more oxidized carbohydrate moieties and the active aminooxy group on the PSA;
wherein said modified blood coagulation protein has a specific activity of at least 50% relative to an unmodified blood coagulation protein.
2. The modified blood coagulation protein of claim 1 wherein said blood coagulation protein is a blood coagulation protein with FIX biological activity, and wherein said modified blood coagulation protein has a specific activity of at least 60% relative to an unmodified blood coagulation protein.
3. The modified blood coagulation protein of claim 1 wherein said blood coagulation protein is a blood coagulation protein with FVIII biological activity, and wherein said modified blood coagulation protein has a specific activity of at least 70% relative to an unmodified blood coagulation protein.
4. A method of conjugating a polysialic acid (PSA) containing an active aminooxy group to an oxidized carbohydrate moiety of a blood coagulation protein, comprising contacting said oxidized carbohydrate moiety with at least one activated PSA under conditions that allow conjugation;
said blood coagulation protein selected from the group consisting of
i) a blood coagulation protein with FIX biological activity; and
ii) a blood coagulation protein with FVIII biological activity;
said carbohydrate moiety oxidized by incubation with a buffer comprising an oxidizing agent selected from the group consisting of sodium periodate (NaIO 4 ), lead tetraacetate (Pb(OAc) 4 ) and potassium perruthenate (KRuO4); wherein an oxime linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the PSA;
said modified blood coagulation protein having a specific activity of at least 50% relative to an unmodified blood coagulation protein.
5. The method of claim 4 wherein said blood coagulation protein is a blood coagulation protein with FIX biological activity, and wherein said modified blood coagulation protein has a specific activity of at least 60% relative to an unmodified blood coagulation protein.
6. The method of claim 4 wherein said blood coagulation protein is a blood coagulation protein with FVIII biological activity, and wherein said modified blood coagulation protein has a specific activity of at least 70% relative to an unmodified blood coagulation protein.
7. The method according claim 4 wherein the PSA is comprised of about 10-300 sialic acid units.
8. The method according to claim 4 wherein the PSA is prepared by reacting an activated aminooxy linker with oxidized PSA;
wherein the aminooxy linker is selected from the group consisting of:
a) a 3-oxa-pentane-1,5-dioxyamine linker of the formula:
and
b) a 3,6,9-trioxa-undecane-1,11-dioxyamine linker of the formula:
wherein the PSA is oxidized by incubation with a oxidizing agent to form a terminal aldehyde group at the non-reducing end of the PSA.
9. The method according to claim 8 wherein the aminooxy linker is 3-oxa-pentane-1,5-dioxyamine.